Literature DB >> 19733894

9p21 index as estimated by dual-color fluorescence in situ hybridization is useful to predict urothelial carcinoma recurrence in bladder washing cytology.

Shigeto Kawauchi1, Hajime Sakai, Kenzo Ikemoto, Satoshi Eguchi, Motonao Nakao, Hirofumi Takihara, Tomoyuki Shimabukuro, Tomoko Furuya, Atsunori Oga, Hideyasu Matsuyama, Mutsuo Takahashi, Kohsuke Sasaki.   

Abstract

Recent studies have shown that chromosome 9p21 locus is frequently deleted in the early stages of urothelial carcinogenesis. To study the predictive value of the 9p21 aberrations in recurrence of urothelial carcinoma of the urinary bladder, we applied dual-color fluorescence in situ hybridization for 9p21 and chromosome 9 centromere to the bladder washing cytology samples that were obtained from the patients with urothelial carcinoma of the urinary bladder treated by transurethral resection. For the evaluation, the 9p21 index was defined as the ratio of the mean number of 9p21 signals per nucleus for that of the chromosome 9 centromere signals per nucleus in each of the bladder washing cytology samples. The 9p21 index values of the bladder washing cytology samples with no (G0) cytologic atypia were significantly higher than those of the bladder washing cytology samples with moderate (G2) (P < .01) and severe (G3) (P < .001) cytologic atypia, but the index values did not statistically differ from those of the bladder washing cytology samples with mild (G1) cytologic atypia. Recurrence-free survival in the patients with a low 9p21 index value (<0.9) was significantly poorer in comparison with the patients with a high 9p21 index value (>0.9). Furthermore, 2 patients of bladder washing cytology G1 with a low 9p21 index value recurred much sooner than the other patients of the bladder washing cytology G1 category. These findings indicate that a decreased 9p21 index value is associated with recurrence of urothelial carcinoma of the urinary bladder, and the 9p21 index may be useful as a marker to identify patients with elevated risk of recurrence of urothelial carcinoma of the urinary bladder.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19733894     DOI: 10.1016/j.humpath.2009.06.011

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  8 in total

Review 1.  Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet?

Authors:  George J Netto
Journal:  Nat Rev Urol       Date:  2011-12-13       Impact factor: 14.432

Review 2.  Emerging critical role of molecular testing in diagnostic genitourinary pathology.

Authors:  George J Netto; Liang Cheng
Journal:  Arch Pathol Lab Med       Date:  2012-04       Impact factor: 5.534

3.  Personalized therapy for urothelial cancer: review of the clinical evidence.

Authors:  Elizabeth A Guancial; Dipanjan Chowdhury; Jonathan E Rosenberg
Journal:  Clin Investig (Lond)       Date:  2011-04

4.  The Immunohistochemical Expression of SOX-10 in Urothelial Carcinoma and the Non Neoplastic Urothelium; and a Correlation with the Tumor Features.

Authors:  Samar Amer; Heba Ibrahim; Miran Elkordy
Journal:  Asian Pac J Cancer Prev       Date:  2022-04-01

Review 5.  Understanding the molecular pathogenesis and prognostics of bladder cancer: an overview.

Authors:  Ming Zhao; Xiang-Lei He; Xiao-Dong Teng
Journal:  Chin J Cancer Res       Date:  2016-02       Impact factor: 5.087

Review 6.  Urinary Bladder Cancer: Biomarkers and Target Therapy, New Era for More Attention.

Authors:  Amrallah A Mohammed; Hani El-Tanni; Hani M El-Khatib; Ahmad A Mirza; Abdulrahim A Mirza; Turki H Alturaifi
Journal:  Oncol Rev       Date:  2016-12-14

7.  Positive urinary fluorescence in situ hybridization indicates poor prognosis in patients with upper tract urothelial carcinoma.

Authors:  Bao Guan; Yicong Du; Xiaohong Su; Zhenpeng Cao; Yifan Li; Yonghao Zhan; Ding Peng; Gengyan Xiong; Dong Fang; Yi Ding; Shiming He; Yanqing Gong; Qun He; Xuesong Li; Liqun Zhou
Journal:  Oncotarget       Date:  2018-01-04

8.  Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy.

Authors:  Simeon U Springer; Chung-Hsin Chen; Maria Del Carmen Rodriguez Pena; Lu Li; Christopher Douville; Yuxuan Wang; Joshua David Cohen; Diana Taheri; Natalie Silliman; Joy Schaefer; Janine Ptak; Lisa Dobbyn; Maria Papoli; Isaac Kinde; Bahman Afsari; Aline C Tregnago; Stephania M Bezerra; Christopher VandenBussche; Kazutoshi Fujita; Dilek Ertoy; Isabela W Cunha; Lijia Yu; Trinity J Bivalacqua; Arthur P Grollman; Luis A Diaz; Rachel Karchin; Ludmila Danilova; Chao-Yuan Huang; Chia-Tung Shun; Robert J Turesky; Byeong Hwa Yun; Thomas A Rosenquist; Yeong-Shiau Pu; Ralph H Hruban; Cristian Tomasetti; Nickolas Papadopoulos; Ken W Kinzler; Bert Vogelstein; Kathleen G Dickman; George J Netto
Journal:  Elife       Date:  2018-03-20       Impact factor: 8.140

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.